DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Thyroid Cancer” report has been added to ResearchAndMarkets.com’s
offering.
This Market Spotlight report covers the thyroid cancer market,
comprising key marketed and pipeline drugs, clinical trials, recent
events and analyst opinion, key upcoming and regulatory events,
probability of success, patent information, a 10-year disease incidence
and five-year prevalence forecast, and licensing and acquisition deals,
as well as presenting drug-specific revenue forecasts
Key Takeaways:
-
The report estimates that in 2017, there were 559,800 incident cases
of thyroid cancer worldwide, and expects that number to increase to
612,600 incident cases by 2026. -
In the same year, there were an estimated 2.0 million five-year
prevalent cases of thyroid cancer worldwide, which is expected to
increase to 2.2 million by 2026. -
The approved drugs in the thyroid cancer space focus on a wide variety
of targets. These drugs are commonly administered via the oral route,
with one product being available in an intramuscular formulation. -
The majority of industry-sponsored drugs in active clinical
development for thyroid cancer are in Phase II, with two drugs in
Phase I. -
Therapies in early-to-mid-stage development for thyroid cancer focus
on targets such as RET, microtubules (tubulin), carcinoembryonic
antigen/immune system, tumor necrosis factor-alpha, and ErbB3/HER3.
These therapies are administered via the oral, intravenous, and
subcutaneous routes. -
The only high-impact upcoming event in the thyroid cancer space is
topline Phase II trial results for GI-6207. The overall likelihood of
approval of a Phase I solid tumors asset is 5.7%, and the average
probability a drug advances from Phase III is 39.4%. Drugs, on
average, take 9.5 years from Phase I to approval, compared to 9.2
years in the overall oncology space. -
There have been 13 licensing and asset acquisition deals involving
thyroid cancer drugs during 2014-19. The $1,550m exclusive global
collaboration signed in November 2017 between Bayer and Loxo Oncology
for the development and commercialization of two novel oncology
therapies selectively targeting genetic drivers of cancer was the
largest deal. -
The distribution of clinical trials across Phase I-IV indicates that
the vast majority of trials for thyroid cancer have been in the early
and mid-phases of development, with 91% of trials in Phase I-II, and
only 9% in Phase III-IV. -
The US has a substantial lead in the number of thyroid cancer clinical
trials globally. France leads the major EU markets, while China has
the top spot in Asia. -
Clinical trial activity in the thyroid cancer space is dominated by
completed trials. Pfizer has the highest number of completed clinical
trials for thyroid cancer, with 28 trials. -
Novartis leads industry sponsors with the highest number of clinical
trials for thyroid cancer, followed by Pfizer.
Key Topics Covered:
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
Thyroid cancer subtypes
TREATMENT
Surgery
Radioactive iodine (RAI) therapy
Thyroid hormone therapy
External beam radiation therapy
Targeted therapy
EPIDEMIOLOGY
MARKETED DRUGS
PIPELINE DRUGS
RECENT EVENTS AND ANALYST OPINION
Selumetinib for Thyroid Cancer (July 26, 2018)
LOXO-292 for Thyroid Cancer (June 2, 2018)
Lenvima for Thyroid Cancer (March 7, 2018)
Cabometyx / Cometriq for Thyroid Cancer (February 13, 2018)
KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
Bayer Files Larotrectinib In EU As LOXO-292 Hurtles Towards The Market
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
Lift-Off For Lilly In Cancer Genetics With Loxo Buy
PARENT PATENTS
REVENUE OPPORTUNITY
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
BIBLIOGRAPHY
Prescription information
APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/pc0yn7
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Thyroid
Cancer Drugs